CYRS1542 / Cyrus Therap - LARVOL DELTA

High CRBN expression in neuroendocrine cancer creates a vulnerability to GSPT1 molecular glue degraders: Target indication selection for CYRS1542 development (AACR 2025) - "Finally, CYRS1542 demonstrated effects similar to CYRS381 in comparable experiments, further supporting the selection of NE cancers as the lead indication for its clinical trials. Overall, these findings highlight CRBN as a key determinant of GSPT1 MGD efficacy and underscore the potential of CYRS1542 as a targeted therapeutic option for aggressive NE cancers."

Endocrine Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor • CRBN • GSPT1

Pharmacological characterization of CYRS1542: A potent and orally available GSPT1 molecular glue degrader for the treatment of neuroendocrine solid cancer with a favorable safety profile (AACR 2024) - "In various NEC in vivo models, including an orthotopic model, CYRS1542 demonstrated dose-dependent and excellent anti-tumor efficacy comparable to the clinical stage GSPT1 MGD. Furthermore, it demonstrates improved safety profiles in a broad spectrum of normal cells, resulting in a higher therapeutic index compared to the clinical GSPT1 MGD."

Clinical • Endocrine Cancer • Genito-urinary Cancer • Hematological Malignancies • Lung Cancer • Neuroendocrine Tumor • Oncology • Prostate Cancer • Small Cell Lung Cancer • Solid Tumor • CRBN • GSPT1 • RB1

Cyrus announces research results on anticancer drugs targeting GSPT1, SOS1, and CDK7 at the U.S. AACR [Google translation] (HIT News) - "Cyrus...announced on the 8th...that it had made three presentations at the American Association for Cancer Research...Through this announcement, the company revealed the results showing that CYRS1542 was effective in treating neuroendocrine tumors (small cell lung cancer, neuroendocrine prostate cancer, etc.) that have a very poor clinical prognosis and lack appropriate treatment options. They also disclosed various cell and animal test results showing that it has a wider therapeutic index compared to competing clinical-stage substances...the drug efficacy evaluation results of various rodent models transplanted with KRAS or EGFR mutant non-small cell carcinoma (NSCLC) or pancreatic cancer (PDAC) cells showed that CK-1001 combination therapy kills cancer cells better than existing treatments....C-16661 had high selectivity for CDK7 and properties suitable for oral administration, and strongly inhibited the growth of various cancer cells."

Preclinical • Lung Cancer • Neuroendocrine Tumor • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Prostate Cancer • Small Cell Lung Cancer • Solid Tumor

Cyrus announces research results of anticancer drugs targeting GSPT1, SOS1, and EGFR [Google translation] (HIT News) - "Cyrus Therapeutics (CEO Kim Byeong-moon, hereinafter Cyrus) disclosed the results of preclinical trials of 'GSPT1 decomposer' and 'SOS1 inhibitor' for the first time at the American Association for Cancer Research (AACR 2023) held from the 14th to the 19th (local time). announced on the 18th....According to Cyrus, in this announcement, the company presents the selective and sustained degradation of GSPT1 of its candidate substance 'CYRS1542 (development code name)', drug efficacy sensitivity according to cancer cell characteristics, and excellent degradation selectivity for cancer cells compared to normal cells."

Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor